Bank of Hawaii Acquires Shares of 19,218 Arrowhead Pharmaceuticals, Inc. $ARWR

Bank of Hawaii acquired a new stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 19,218 shares of the biotechnology company’s stock, valued at approximately $1,276,000.

Several other hedge funds have also recently modified their holdings of the stock. Royal Bank of Canada increased its holdings in shares of Arrowhead Pharmaceuticals by 30.2% in the first quarter. Royal Bank of Canada now owns 45,239 shares of the biotechnology company’s stock worth $576,000 after purchasing an additional 10,496 shares during the last quarter. AQR Capital Management LLC bought a new stake in Arrowhead Pharmaceuticals in the first quarter worth $514,000. Goldman Sachs Group Inc. raised its stake in Arrowhead Pharmaceuticals by 34.6% during the first quarter. Goldman Sachs Group Inc. now owns 1,741,666 shares of the biotechnology company’s stock valued at $22,189,000 after purchasing an additional 447,456 shares in the last quarter. Empowered Funds LLC raised its stake in Arrowhead Pharmaceuticals by 6.9% during the first quarter. Empowered Funds LLC now owns 15,252 shares of the biotechnology company’s stock valued at $194,000 after purchasing an additional 979 shares in the last quarter. Finally, Focus Partners Wealth lifted its position in Arrowhead Pharmaceuticals by 1,339.5% during the first quarter. Focus Partners Wealth now owns 16,252 shares of the biotechnology company’s stock valued at $207,000 after purchasing an additional 15,123 shares during the last quarter. Hedge funds and other institutional investors own 62.61% of the company’s stock.

Analyst Upgrades and Downgrades

ARWR has been the topic of a number of research reports. Royal Bank Of Canada boosted their target price on shares of Arrowhead Pharmaceuticals from $80.00 to $87.00 and gave the stock an “outperform” rating in a report on Friday, May 8th. Morgan Stanley upgraded Arrowhead Pharmaceuticals from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $78.00 to $100.00 in a research report on Tuesday, April 21st. JPMorgan Chase & Co. began coverage on Arrowhead Pharmaceuticals in a research note on Friday, May 1st. They set an “overweight” rating and a $88.00 price objective on the stock. Sanford C. Bernstein upped their price objective on Arrowhead Pharmaceuticals from $35.00 to $46.00 and gave the company a “market perform” rating in a research report on Wednesday, May 13th. Finally, Leerink Partners raised their price objective on Arrowhead Pharmaceuticals from $61.00 to $72.00 and gave the company a “market perform” rating in a research note on Wednesday. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Arrowhead Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $86.36.

Arrowhead Pharmaceuticals Stock Performance

Arrowhead Pharmaceuticals stock opened at $81.82 on Friday. Arrowhead Pharmaceuticals, Inc. has a fifty-two week low of $14.30 and a fifty-two week high of $84.55. The company has a market capitalization of $11.53 billion, a PE ratio of -38.06 and a beta of 1.28. The company has a 50 day moving average price of $74.25 and a 200-day moving average price of $67.68. The company has a debt-to-equity ratio of 1.41, a quick ratio of 6.23 and a current ratio of 6.23.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its earnings results on Thursday, May 7th. The biotechnology company reported ($0.93) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.10) by $0.17. Arrowhead Pharmaceuticals had a negative return on equity of 55.09% and a negative net margin of 48.38%.The business had revenue of $73.74 million during the quarter, compared to analyst estimates of $73.84 million. During the same period in the previous year, the company posted $2.75 EPS. Arrowhead Pharmaceuticals’s revenue was down 86.4% on a year-over-year basis. As a group, equities analysts forecast that Arrowhead Pharmaceuticals, Inc. will post -3 earnings per share for the current year.

Insider Activity at Arrowhead Pharmaceuticals

In related news, insider James C. Hamilton sold 10,000 shares of the company’s stock in a transaction dated Thursday, April 23rd. The shares were sold at an average price of $75.00, for a total value of $750,000.00. Following the completion of the sale, the insider directly owned 226,958 shares of the company’s stock, valued at $17,021,850. This represents a 4.22% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Daniel Joseph Apel sold 13,095 shares of the stock in a transaction dated Wednesday, April 22nd. The stock was sold at an average price of $71.35, for a total transaction of $934,328.25. Following the transaction, the chief financial officer owned 162,905 shares in the company, valued at approximately $11,623,271.75. The trade was a 7.44% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 26,065 shares of company stock worth $1,912,662 over the last three months. 3.60% of the stock is owned by corporate insiders.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.